Income Statement Evolution: PHAXIAM Therapeutics S.A.

Balance Sheet Analysis: PHAXIAM Therapeutics S.A.

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 -59.1 -17 -8.32 -25.2 - 7 15.6 4.8
Change - -71.24% -51.06% 202.88% - - 122.86% -69.23%
Announcement Date 3/16/20 3/8/21 4/27/22 3/22/23 3/20/24 - - -
1EUR in Million
Estimates

Cash flow: PHAXIAM Therapeutics S.A.

Fiscal Period: December 2019 2020 2021 2022 2024 2025 2026
CAPEX 1 20.12 1.139 0.298 - 0.5 0.5 0.5
Change - -94.34% -73.84% - - 0% 0%
Free Cash Flow (FCF) 1 -63.43 -52.86 -57.07 -31.85 0.2 1.15 -19.5
Change - -16.66% 7.96% -44.19% - 475% -1,795.65%
Announcement Date 3/16/20 3/8/21 4/27/22 3/22/23 - - -
1EUR in Million
Estimates

Financial Ratios: PHAXIAM Therapeutics S.A.

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025 2026

Profitability

         
EBITDA Margin (%) - -1,133.03% -1,717.08% -1,223.4% 5.88% - -1,666.67% -1,125% -
EBIT Margin (%) - -1,212.83% -1,851.32% -1,352.03% -9.02% - -1,819.05% -1,384.37% -
EBT Margin (%) - -1,186.07% -1,971.41% -1,286.96% - - - - -
Net margin (%) - -1,186.05% -1,971.49% -1,287.01% -0.73% - -1,647.62% -1,234.38% -
FCF / Net Income (%) - -1,200.59% -1,421.71% -1,365.26% -102.75% - 19.05% 71.87% -

Profitability

         
ROA -15.02% -27.97% -43.25% -48% -30.14% -25.54% - - -
ROE -23.38% -54.21% -130.78% -217.87% -0.98% -95.68% - - -

Financial Health

         
Leverage (Debt/EBITDA) - - - - - - -0.4x -0.87x -0.26x
Debt / Free cash flow - - - - - - 35x 13.57x -0.25x

Capital Intensity

         
CAPEX / Current Assets (%) - 380.79% 30.63% 7.13% - - 47.62% 31.25% -
CAPEX / EBITDA (%) - -33.61% -1.78% -0.58% - - -2.86% -2.78% -2.7%
CAPEX / FCF (%) - -31.72% -2.15% -0.52% - - 250% 43.48% -2.56%

Items per share

         
Cash flow per share 1 - -24.14 - - - - 2.7 3.4 -
Change - - - - - - - 125.93% -
Dividend per Share 1 - - - - - - - - -
Change - - - - - - - - -
Book Value Per Share 1 - 47.7 14.43 9.642 7.573 - - - -
Change - - -69.74% -33.2% -21.46% - - - -
EPS 1 - -34.9 -39.9 -22.7 -0.1 -5 -1.82 -0.91 -0.62
Change - - 14.33% -43.11% -99.56% 4,900% -63.6% 50% 68.13%
Nbr of stocks (in thousands) - 1,794 1,956 3,102 3,102 6,075 9,980 9,980 9,980
Announcement Date - 3/16/20 3/8/21 4/27/22 3/22/23 3/20/24 - - -
1EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.954EUR
Average target price
5.100EUR
Spread / Average Target
+161.00%
Consensus

Profit revisions

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. PHXM Stock
  4. Financials PHAXIAM Therapeutics S.A.